Novel Updates in DLBCL and MCL Treatment Research From the 2024 ASCO Meeting
John Burke, MD, Rocky Mountain Cancer Centers, Englewood, Colorado speaks about some of the most interesting topics in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) treatment research presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Transcript:
Hello, I'm John Burke from Rocky Mountain Cancer Centers. One interesting paper that got presented yesterday was looking at the addition of the antibody drug conjugate brentuximab vedotin to a backbone of lenalidomide and rituximab in patients with relapsed diffuse large B-cell lymphoma. It showed that the addition of brentuximab did improve all of the end points, including response rate, progression-free survival, and overall survival. It raises the question as to whether that would be a regimen that could be useful in patients with relapsed DLBCL. That was a new finding at the meeting.
Equally interesting was that they found that brentuximab targets CD30 and they found that it works not only in patients whose DLBCL expressed CD30, but also those whose DLBCL did not express CD30, so that was also a new finding. Brentuximab vedotin has been studied in DLBCL for many years, and in fact I personally thought it was kind of dead in the water because it hadn't really proven a benefit, but this study actually showed that it truly does have activity, and could be a potentially useful tool for patients with DLBCL. That was one interesting finding yesterday that was novel.
We also saw interesting follow-up on glofitamab in patients with mantle cell lymphoma. Glofitamab [is] a bispecific antibody targeting CD3 and CD20 that shows strong activity in patients with mantle cell lymphoma. [It] certainly makes you think that that could be a useful tool for patients in the near future.
Those were some of the more interesting presentations in the lymphoma session yesterday.
Source:
Burke, J. Recorded at the ASCO Annual Meeting. May 31–June 4, 2024; Chicago, IL.
